QUALITY CONTROL ASSESSMENT OF DUTASTERIDE AND SILODOSIN IN CAPSULES AND TABLETS EMPLOYING A NOVEL DEVELOPED HPLC TECHNIQUE; EVALUATION OF STABILITIES OF DUTASTERIDE AND SILODOSIN IN ACCELERATED DEGRADATION

KADALI JAGADEESH; K. GANESH KADIYALA; B. N. SURESH VARMA DENDUKURI; RAMA SWAMY GUTTULA; V. L. N. BALAJI GUPTA TIRUVEEDHI; PEDDINTI VAMSI; RAJYA LAKSHMI CHAVAKULA

doi:10.22159/ijap.2023v15i6.49036

Authors

KADALI JAGADEESH Department of Chemistry, Shri Vishnu Engineering College for Women (A), Bhimavaram-534202, Andhra Pradesh, India https://orcid.org/0000-0002-3805-4931
K. GANESH KADIYALA Department of Chemistry, Shri Vishnu Engineering College for Women (A), Bhimavaram-534202, Andhra Pradesh, India https://orcid.org/0000-0001-7357-0504
B. N. SURESH VARMA DENDUKURI Department of Chemistry, Shri Vishnu Engineering College for Women (A), Bhimavaram-534202, Andhra Pradesh, India
RAMA SWAMY GUTTULA Department of BS, Vishnu Institute of Technology, Bhimavaram-534202, Andhra Pradesh, India
V. L. N. BALAJI GUPTA TIRUVEEDHI Department of BS, Vishnu Institute of Technology, Bhimavaram-534202, Andhra Pradesh, India https://orcid.org/0000-0003-3806-8820
PEDDINTI VAMSI Department of Chemistry, Sir C R Reddy Autonomous College, Eluru-534007, Andhra Pradesh, India
RAJYA LAKSHMI CHAVAKULA Department of BS, Vishnu Institute of Technology, Bhimavaram-534202, Andhra Pradesh, India https://orcid.org/0000-0002-9037-1010

DOI:

https://doi.org/10.22159/ijap.2023v15i6.49036

Keywords:

Prostatic hyperplasia, Dutasteride, Silodosin, Quality control, Capsule, Tablet, Stability

Abstract

Objective: The combination of dutasteride (DTRE) plus silodosin (SLDN) is used for treating acute urine retention brought upon by benign prostatic hyperplasia in men. The contents of DTRE and SLDN in capsules and tablets must be monitored for quality. In this research, a quick, selective and robust stability indicating HPLC method has been developed for concurrent assay of DTRE and SLDN in capsules and tablets. Also, the stabilities of DTRE and SLDN under several types of applied stress were determined.

Methods: Analysis performed using Xterra Symmetry type column C18 (“4.6 mm x 150 mm, 5 mm” dimensions) and mobile phase having 0.1N strength, 20% volume fraction of dipotassium hydrogen phosphate and 80% volume fraction of pure form acetonitrile; PDA analysis was made at 265 nm. Stabilities of DTRE and SLDN were determined under several types of applied stress, including thermal, basic, oxidative, photo, and acid.

Results: The elution times for DTRE and SLDN were 2.003 min and 3.377 min, respectively. DTRE and SLDN linear ranges were 20–120 µg/mL and 1.25–7.5 µg/mL, respectively. Method is precise with 0.2498% (DTRE) and 0.0773% (SLDN) RSD values. Method is accurate with 98.913-101.049% (DTRE) and 100.023-100.162% (SLDN) recovery values. In degradation investigation, degradant’s peaks elution times are different from the elution times of DTRE and SLDN. Thus, proved specificity and stability indicating power of the method. DTRE and SLDN were found relatively stable in thermal and were found sensitive in oxidation. In overall, SLDN found more sensitive to applied stress, including thermal, basic, oxidative, photo, and acid compared to DTRE.

Conclusion: Finally, this developed analytical approach was efficaciously applied to a commercial capsule and tablet formulations containing fixed dose of DTRE and SLDN, demonstrating its usefulness for quality control and degradation investigations on DTRE and SLDN.

Downloads

Download data is not yet available.

References

Lokeshwar SD, Harper BT, Webb E, Jordan A, Dykes TA, Neal DE Jr. Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Transl Androl Urol. 2019;8(5):529-39. doi: 10.21037/tau.2019.10.01, PMID 31807429.

Chughtai B, Forde JC, Thomas DD, Laor L, Hossack T, Woo HH. Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016;2:16031. doi: 10.1038/nrdp.2016.31, PMID 27147135.

Noweir A, Abusamra A, Al Zarooni A, Binbay M, Doble A, Tariq L. Prevalence of benign prostatic hyperplasia among the adult general population of five Middle Eastern Countries: results of the SNAPSHOT programme. Arab J Urol. 2022;20(1):14-23. doi: 10.1080/2090598X.2021.2010451, PMID 35223105.

Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148-51. doi: 10.1016/j.ajur.2017.06.004, PMID 29264223.

Hagiwara K, Koie T, Iwamura H, Imai A, Hatakeyama S, Yoneyama T. Efficacy and safety of silodosin and dutasteride combination therapy in acute urinary retention due to benign prostatic hyperplasia: a single-arm prospective study. BioMed Res Int. 2016;2016:4975851. doi: 10.1155/2016/4975851, PMID 27195288.

Silodosin and dutasteride capsules. Available from: https://www.indiamart/proddetail/silodosin-and-dutasteride-capsules-15301151462.html. [Last accessed on 28 Sep 2023]

Silodosin and dutasteride tablets. Available from: https://www.indiamart/proddetail/silodosin-dutasteride-tablets-20298346973.html. [Last accessed on 28 sep 2023]

Jindan L, Xiao W, Liping X. Evolving role of silodosin for the treatment of urological disorders–a narrative review. Drug Des Devel Ther. 2022;16:2861-84. doi: 10.2147/DDDT.S373659, PMID 36051157.

Toren P, Margel D, Kulkarni G, Finelli A, Zlotta A, Fleshner N. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study. BMJ. 2013;346:f2109. doi: 10.1136/bmj.f2109, PMID 23587564.

Haleem RM, Salem MY, Fatahallah FA, Abdelfattah LE. Quality in the pharmaceutical industry-a literature review. Saudi Pharm J. 2015;23(5):463-9. doi: 10.1016/j.jsps.2013.11.004, PMID 26594110.

Lahai M, Conteh EBS, Mansaray AF, Amara J, Bawoh M, Komeh JP. Evaluation of the quality of different brands of ascorbic acid in Freetown, Sierra Leone. Int J Pharm Pharm Sci. 2021;13(9):22-6. doi: 10.22159/ijpps.2021v13i9.41230.

Sardella M, Belcher G, Lungu C, Ignoni T, Camisa M, Stenver DI. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance. Ther Adv Drug Saf. 2021;12:20420986211038436. doi: 10.1177/20420986211038436, PMID 34394910.

Nataraj KS, Srinivasa RA, Harshitha S, Pravallika K. Analytical method development and validation for the estimation of silodosin and dutasteride in capsule dosage form by RP-HPLC method. J Drug Metab Toxicol. 2020;11(2):1-8. doi: 10.35248/2157-7609.20.11.245.

Kattempudi P, Ramarao N. Simultaneous estimation of dutasteride and silodosin in bulk form by RP-HPLC method. World J Curr Pharm Res. 2019;1(5):148-63.

Hardik PS, Amit K, Shirish D, Shashikant B. Novel RP-HPLC method for simultaneous estimation of silodosin and dutasteride in multiunit solid dosage form. Res J Pharm Biol Chem Sci. 2014;5(2):801-10.

Briscoe CJ, Hage DS. Factors affecting the stability of drugs and drug metabolites in biological matrices. Bioanalysis. 2009;1(1):205-20. doi: 10.4155/bio.09.20, PMID 21083197.

Wotring VE. Chemical potency and degradation products of medications stored over 550 earth days at the international space station. AAPS J. 2016;18(1):210-6. doi: 10.1208/s12248-015-9834-5, PMID 26546565.

Tabassum R, Rizwan SH. Stability indicating analytical method development and validation for the estimation of Ruxolitinib in bulk and pharmaceutical dosage form using UPLC. Int J Pharm Pharm Sci. 2023;15(2):40-6. doi: 10.22159/ijpps.2023v15i2.46839.

Damle MC, Meshram P. Development and validation of stability indicating high-performance thin layer chromatographic method for budesonide. Asian J Pharm Clin Res. 2023;16(12).

Chandar PB, Madhuri MS, Hyma KN, Anusha S, Rasool SN. ARP-HPLC stability indicating method development and validation for the simultaneous determination of netupitant and palonosetron in pharmaceutical dosage form. Int J Curr Pharm Sci. 2022;14(4):60-7. doi: 10.22159/ijcpr.2022v14i4.1985.

ICH Harmonized tripartite Guideline q1a. Stability testing of new drug substances and products. Vol. R2. Geneva; 2003.

ICH Harmonized tripartite Guideline q1a. Validation of analytical procedures technical requirements for registration of pharmaceuticals for human use. Vol. R1. Geneva; 2005.

Sharma S, Goyal S, Chauhan K. A review on analytical method development and validation. Int J App Pharm. 2018;10(6):8-15. doi: 10.22159/ijap.2018v10i6.28279.

Broadhurst D, Goodacre R, Reinke SN, Kuligowski J, Wilson ID, Lewis MR. Guidelines and considerations for the use of system suitability and quality control samples in mass spectrometry assays applied in untargeted clinical metabolomic studies. Metabolomics. 2018;14(6):72. doi: 10.1007/s11306-018-1367-3, PMID 29805336.

Snyder LR, Dolan JW. Optimizing selectivity during reversed-phase high performance liquid chromatography method development: prioritizing experimental conditions. J Chromatogr A. 2013;1302:45-54. doi: 10.1016/j.chroma.2013.05.082, PMID 23830242.

Kim HY. Statistical notes for clinical researchers: simple linear regression 3-residual analysis. Restor Dent Endod. 2019;44(1):e11. doi: 10.5395/rde.2019.44.e11, PMID 30834233.

Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29Suppl 1:S49-52. PMID 18852857.

Betz JM, Brown PN, Roman MC. Accuracy, precision, and reliability of chemical measurements in natural products research. Fitoterapia. 2011;82(1):44-52. doi: 10.1016/j.fitote.2010.09.011, PMID 20884340.

Dejaegher B, Heyden YV. Ruggedness and robustness testing. J Chromatogr A. 2007;1158(1-2):138-57. doi: 10.1016/j.chroma.2007.02.086, PMID 17379230.

Osel N, Planinšek Parfant T, Kristl A, Roskar R. Stability-Indicating analytical approach for stability evaluation of lactoferrin. Pharmaceutics. 2021;13(7):1065. doi: 10.3390/pharmaceutics13071065, PMID 34371755.